AstraZeneca (Singapore)

Recent papers from AstraZeneca (Singapore)

1. Qualitative in-trial interviews: a targeted literature review exploring objectives and methodsJournal of Patient-Reported Outcomes · 2026
2. Absorption, distribution, metabolism and excretion of londamocitinib after single‐dose inhaled, intravenous and oral administration in healthy participantsBritish Journal of Clinical Pharmacology · 2026
3. Proteome-guided drug discovery maps and mitigates therapeutic degrader toxicityNature Chemical Biology · 2026
4. The Future of all‐Comers Trials in the Era of Precision OncologyClinical Pharmacology & Therapeutics · 2026
5. Regulatory T cell heterogeneity: who they are, where they come from, and where they goFrontiers in Immunology · 2026
6. Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancerBritish Journal of Cancer · 2026
7. Understanding mechanisms of PARP inhibitor resistancenpj Breast Cancer · 2026
8. Population Pharmacokinetics and Exposure–response Analysis of Durvalumab in Patients with Limited-stage Small-cell Lung Cancer in the Phase 3 ADRIATIC StudyThe AAPS Journal · 2026
9. Real-world treatment patterns and associated outcomes in patients with HER2-positive unresectable or metastatic breast cancer: the HER2 REAL StudyESMO Open · 2026
10. Benchmarking Hierarchical Double-Ended Transition-State Search Methods for Metal-Catalyzed ReactionsJournal of Chemical Theory and Computation · 2026
11. Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH studyClinical Cancer Research · 2026
12. The Batch Nature of Continuous Flow Production via Natural-Abundance Stable IsotopesOrganic Process Research & Development · 2026
13. Enhancing access to oral cancer medicines in Lebanon: exploring innovative benefit package designs in private insuranceBMC Health Services Research · 2026
14. Next‐Generation Manufacturing: The Evolving Role of Biocatalysis in AstraZenecaChemBioChem · 2026
15. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohortESMO Open · 2026
16. Chemogenomic maps reveal a PRDX1-dependent iron–damage axis in the DNA damage responseNature Chemical Biology · 2026
17. Generative Active Learning for Molecular Design with REINVENT: Balancing Binding Affinity and Synthetic AccessibilityJournal of Chemical Theory and Computation · 2026
18. Autologous Glypican-3–Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102Cancer Immunology Research · 2026
19. Osimertinib After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and PPO From the Phase III LAURA StudyClinical Cancer Research · 2026
20. Tozorakimab to Prevent COPD ExacerbationsNew England Journal of Medicine · 2026